scholarly journals Effects of testosterone replacement on serotonin levels in the prostate and plasma in a murine model of hypogonadism

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Paulo Mota ◽  
João Barbosa-Martins ◽  
Rute S. Moura ◽  
Estêvão Lima ◽  
Alice Miranda ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Murine Model ◽  
Benign Prostate Hyperplasia ◽  
The Other ◽  
Prostate Hyperplasia ◽  
Before And After ◽  
Prostate Growth ◽  
The Impact ◽  
Benign Prostate ◽  
Plasmatic Concentration

Abstract Benign prostate hyperplasia is a dysfunctional disease with an elevated prevalence. Despite the accepted impact of aging and testosterone (TES) in its pathophysiology, its aetiology remains unknown. Recent studies described that serotonin (5-HT) inhibits benign prostate growth through the modulation of the androgen receptor, in the presence of TES. Accordingly, this work aimed to determine the impact of castration and TES replacement in plasmatic and prostatic 5-HT regulation. C57BL/6 mice were submitted to surgical castration and divided into three groups, continually exposed to either vehicle or different TES doses for 14 days. Plasmatic 5-HT concentration was measured before and after castration, and after TES reintroduction. Finally, total prostatic weight and intra-prostatic 5-HT were determined in the different groups. Our results demonstrate that mice prostate exhibits high 5-HT tissue levels and that intra-prostatic total 5-HT was independent of castration or TES reintroduction, in all studied groups. Also, 5-HT plasmatic concentration significantly increased after castration and then normalized after TES administration. Our findings revealed that mice prostate has a high 5-HT content and that total prostatic 5-HT levels do not depend on androgens’ action. On the other hand, castration induced a significant increase in plasmatic 5-HT concentration, raising the hypothesis that androgens might be regulating the production of extra-prostatic 5-HT.

scholarly journals Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia

2004 ◽  
pp. 591-603 ◽  
Author(s):  
C Crescioli ◽  
P Ferruzzi ◽  
A Caporali ◽  
M Scaltriti ◽  
S Bettuzzi ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Phase Ii ◽  
Benign Prostate Hyperplasia ◽  
Ventral Prostate ◽  
Double Blind ◽  
Prostate Hyperplasia ◽  
Prostate Cell ◽  
Prostate Growth ◽  
Benign Prostate

OBJECTIVE: Calcitriol analogues might represent an interesting new therapy for benign prostate hyperplasia (BPH). We here report the preclinical characterization of BXL-628, an analogue selected for an ongoing double-blind, randomized, placebo-controlled phase II trial in BPH. DESIGN: Experiments with BXL-628 were carried out in human BPH cells and in the ventral prostate of intact and castrated rats. METHODS: BPH cell and rat prostate growth were evaluated along with morphological and biochemical hallmarks of apoptosis. RESULTS: BXL-628 inhibited human BPH cell proliferation and induced apoptosis even in the presence of androgens or growth factors. It also decreased prostate growth to an extent similar to finasteride, inducing DNA fragmentation and apoptosis, both in intact and in testosterone-supplemented castrated rats. Accordingly, BXL-628, like finasteride, increased the expression of clusterin, a prostatic atrophy marker. However, BXL-628 did not inhibit 5 alpha-reductase 1 and 2, did not bind to the androgen receptor (AR) in BPH homogenates and did not affect AR-coupled luciferase activity. In addition, BXL-628 did not affect rat pituitary and testis activity or calcemia. CONCLUSIONS: BXL-628 inhibited in vitro and in vivo prostate cell proliferation, and therefore might represent a novel, interesting option for the treatment of BPH.

scholarly journals Nocturia and benign prostatic hyperplasia

2008 ◽  
Vol 65 (10) ◽  
pp. 751-754
Author(s):  
Darko Laketic ◽  
Vesna Laketic
Keyword(s):  
Benign Prostate Hyperplasia ◽  
Control Group ◽  
Favorable Result ◽  
Prostate Hyperplasia ◽  
Factors Associated ◽  
Significant Difference ◽  
Before And After ◽  
Bothersome Symptom ◽  
Group A ◽  
Benign Prostate

Background/Aim. Nocturia often occurs in patients with benign prostate hyperplasia (BPH). The aim of the study was to investigate the frequency of nocturia in patients with BPH. Nocturia and other factors associated with it were also investigated. Methods. Forty patients with the confirmed diagnosis of BPH were studied. Transurethral and transvesical prostatectomy were performed in all the patients. Symptoms were evaluated with the International Prostate Symptom Score before, as well as three and six months after the surgery. All the results were compared with the control group. Results. There was no statistically significant difference between the patients before and after the surgery regarding nocturia. There was, however, a statistically significant difference between the operated patients and the control group regarding nocturia, as well as a statistically significant correlation between noctruia and the age of the patients in both the investigated and the control group. A correlation also existed between nocturia and the prostatic size. Conclusion. There was no statistically significant improvement in symptoms of nocturia after the surgery. It is necessary to be very careful in decision making in patients with nonabsolute indiction for surgery and isolated bothersome symptom of nocturia. Age of a patient should also be considered in the evaluation of favorable result of the surgery because of a significant correlation between noctura and the age of a patient.

scholarly journals Stromal Androgen Receptor Roles in the Development of Normal Prostate, Benign Prostate Hyperplasia, and Prostate Cancer

2015 ◽  
Vol 185 (2) ◽  
pp. 293-301 ◽  
Author(s):  
Simeng Wen ◽  
Hong-Chiang Chang ◽  
Jing Tian ◽  
Zhiqun Shang ◽  
Yuanjie Niu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Benign Prostate Hyperplasia ◽  
Normal Prostate ◽  
Prostate Hyperplasia ◽  
Benign Prostate
Sign in / Sign up

Export Citation Format

Share Document